The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2024 | Elucidating the optimal second-line therapy in metastatic pancreatic cancer
Sara Lonardi, MD, Veneto Institute of Oncology, Padua, Italy, explores the survival outcomes of various second-line regimens in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine plus nab-paclitaxel. Liposomal irinotecan with 5-fluorouracil and leucovorin (nal-IRI+5-FU/LV) outperformed FOLFIRI, FOLFOX/XELOX, and whilst FOLFIRINOX had a modest overall survival, it only benefits a small number of patients. Overall, nal-IRI+5-FU/LV continues to be the preferred second-line option. This interview took place at 2024 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Annual Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
